IDMI @$1.97. See previous post re: European approval of "Mepact" (L-MTP-PE or Junovan) either in February or March 2009. Rodman and Renshaw analyst projects $20M revenue tops in Europe alone. About 29M shares outstanding, x5 revs of $20M= $100M. $100M div by 29M shares= about $3.50 a share.
IDM is either going to be bought out or partner, probably buy-out, since CEO and other executive officers are working part-time at IDM.
I have admit that "Mr. Market" is stumping me re: current share price of about $2.00 on this one. Of course overall market is in a massive deleveraging.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.